These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15041346)

  • 1. Cyclosporine renal dysfunction.
    Vítko S; Viklický O
    Transplant Proc; 2004 Mar; 36(2 Suppl):243S-247S. PubMed ID: 15041346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine nephrotoxicity: associated allograft dysfunction at low trough concentration.
    Jankauskiene A; Druskis V; Laurinavicius A
    Clin Nephrol; 2001 Dec; 56(6):S27-9. PubMed ID: 11770808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
    He X; Johnston A
    Transplant Proc; 2004 Jun; 36(5):1321-6. PubMed ID: 15251323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction.
    Kahan BD
    Transplantation; 2001 Jun; 71(11 Suppl):SS52-7. PubMed ID: 11583490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine in pediatric kidney transplantation.
    Pape L; Ehrich JH; Offner G
    Transplant Proc; 2004 Mar; 36(2 Suppl):203S-207S. PubMed ID: 15041337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience.
    Singh D; Kiberd B; Belitsky P; Fraser A; Balbontin F; Lawen J
    Transplant Proc; 2004 Mar; 36(2 Suppl):414S-419S. PubMed ID: 15041377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation of renal function during maintenance therapy with cyclosporine.
    Serón D; Moreso F
    Transplant Proc; 2004 Mar; 36(2 Suppl):257S-260S. PubMed ID: 15041349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U; Ullrich S; Roskos M; Misselwitz J
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with cyclosporine in the Canary Islands.
    Hernández D
    Transplant Proc; 2004 Mar; 36(2 Suppl):120S-124S. PubMed ID: 15041320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of cyclosporine on the development of immunosuppressive therapy--pediatric transplantation using cyclosporine.
    Hoyer PF; Vester U
    Transplant Proc; 2004 Mar; 36(2 Suppl):197S-202S. PubMed ID: 15041336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
    Hauser IA; Schaeffeler E; Gauer S; Scheuermann EH; Wegner B; Gossmann J; Ackermann H; Seidl C; Hocher B; Zanger UM; Geiger H; Eichelbaum M; Schwab M
    J Am Soc Nephrol; 2005 May; 16(5):1501-11. PubMed ID: 15772250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrarenal activation of renin angiotensin system in the development of cyclosporine A induced chronic nephrotoxicity.
    Shang MH; Yuan WJ; Zhang SJ; Fan Y; Zhang Z
    Chin Med J (Engl); 2008 Jun; 121(11):983-8. PubMed ID: 18706245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
    Falck P; Asberg A; Guldseth H; Bremer S; Akhlaghi F; Reubsaet JL; Pfeffer P; Hartmann A; Midtvedt K
    Transplantation; 2008 Jan; 85(2):179-84. PubMed ID: 18212621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine: from renal transplantation to autoimmune diseases.
    Ponticelli C
    Ann N Y Acad Sci; 2005 Jun; 1051():551-8. PubMed ID: 16126995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year.
    Rowshani AT; Scholten EM; Bemelman F; Eikmans M; Idu M; Roos-van Groningen MC; Surachno JS; Mallat MJ; Paul LC; de Fijter JW; Bajema IM; ten Berge I; Florquin S
    J Am Soc Nephrol; 2006 Jan; 17(1):305-12. PubMed ID: 16306168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression.
    Rintala JM; Savikko J; Rintala SE; von Willebrand E
    Transplant Proc; 2006 Dec; 38(10):3239-40. PubMed ID: 17175234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial.
    Hazzan M; Buob D; Labalette M; Provot F; Glowacki F; Hoffmann M; Copin MC; Noel C
    Transplantation; 2006 Sep; 82(5):657-62. PubMed ID: 16969289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine nephrotoxicity.
    Grinyó JM; Cruzado JM
    Transplant Proc; 2004 Mar; 36(2 Suppl):240S-242S. PubMed ID: 15041345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.